Synonyms: AZ 628 | AZ-628
Compound class:
Synthetic organic
Comment: AZ628 is an experimental inhibitor of RAF kinases [1]. Preclinical data for AZ628 was presented at the AACR Annual Meeting by Shen et al. in 2007 (Linking molecular characteristics to the pharmacological response of a panel of cancer cell lines to the BRAF inhibitor, AZ628).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. (2007)
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets, 11 (12): 1587-609. [PMID:18020980] |
2. Kolch W, Kotwaliwale A, Vass K, Janosch P.
The role of Raf kinases in malignant transformation. Accessed on 24/06/2015. Modified on 24/06/2015. www.expertreviews.org, http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.114.8626&rep=rep1&type=pdf |
3. Wenglowsky S, Ren L, Grina J, Hansen JD, Laird ER, Moreno D, Dinkel V, Gloor SL, Hastings G, Rana S et al.. (2014)
Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase. Bioorg Med Chem Lett, 24 (8): 1923-7. [PMID:24675381] |